Novo Nordisk A/S (NYSE:NVO) Shares Sold by Forte Capital LLC ADV

Forte Capital LLC ADV cut its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 35.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 42,278 shares of the company's stock after selling 22,723 shares during the period. Forte Capital LLC ADV's holdings in Novo Nordisk A/S were worth $3,637,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of NVO. WCM Investment Management LLC lifted its position in Novo Nordisk A/S by 1.0% during the fourth quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company's stock valued at $345,588,000 after buying an additional 40,475 shares in the last quarter. Natixis Advisors LLC lifted its position in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company's stock valued at $366,125,000 after buying an additional 80,070 shares in the last quarter. DSM Capital Partners LLC lifted its position in Novo Nordisk A/S by 16.7% during the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock valued at $172,678,000 after buying an additional 286,912 shares in the last quarter. International Assets Investment Management LLC lifted its position in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock valued at $215,942,000 after buying an additional 1,796,635 shares in the last quarter. Finally, LPL Financial LLC lifted its position in Novo Nordisk A/S by 3.6% during the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company's stock valued at $162,266,000 after buying an additional 47,496 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 5.2 %

Shares of NYSE:NVO traded up $4.33 during midday trading on Friday, reaching $88.07. The company had a trading volume of 15,117,993 shares, compared to its average volume of 9,263,626. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock's fifty day moving average price is $86.39 and its 200-day moving average price is $108.48. The stock has a market capitalization of $395.19 billion, a P/E ratio of 26.77, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a one year low of $77.82 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's payout ratio is presently 47.72%.

Analyst Ratings Changes

A number of research firms have recently commented on NVO. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has an average rating of "Moderate Buy" and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.